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Abstract
Psychotic disorders have long been associated with inflated rates of co-occurring substance use disorders,
termed dual diagnosis. Substance use has devastating effects on symptom severity, healthcare costs, and long
term outcomes in this already at risk population. Although there has been great success in developing
programs with coordinated care, there has been some delay in cultivating psychosocial interventions that
address both disorders in a cohesive manner. Mindfulness Based Relapse Prevention (MBRP) may fill the
treatment gap for dually diagnosed clients. The use of mindfulness strategies for psychosis has shown positive
effects in the reduction of anxiety, hospitalizations, experiential avoidance, and distress surrounding psychotic
symptoms. Similarly, the use of mindfulness is gaining momentum in the treatment of substance use. A fusion
of mindfulness techniques and Relapse Prevention, MBRP provides a wide lens from which to view the
complexities of concurrent disorders, providing a common skill set. In this thesis, evidence for the use of
MBRP for clients who are dually diagnosed with psychotic disorders is reviewed.
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ABSTRACT 
Psychotic disorders have long been associated with inflated rates of co-occurring 
substance use disorders, termed dual diagnosis.  Substance use has devastating effects on 
symptom severity, healthcare costs, and long term outcomes in this already at risk population.  
Although there has been great success in developing programs with coordinated care, there has 
been some delay in cultivating psychosocial interventions that address both disorders in a 
cohesive manner.  Mindfulness Based Relapse Prevention (MBRP) may fill the treatment gap for 
dually diagnosed clients.  The use of mindfulness strategies for psychosis has shown positive 
effects in the reduction of anxiety, hospitalizations, experiential avoidance, and distress 
surrounding psychotic symptoms.  Similarly, the use of mindfulness is gaining momentum in the 
treatment of substance use.  A fusion of mindfulness techniques and Relapse Prevention, MBRP 
provides a wide lens from which to view the complexities of concurrent disorders, providing a 
common skill set.  In this thesis, evidence for the use of MBRP for clients who are dually 
diagnosed with psychotic disorders is reviewed. 
Keywords:  dual diagnosis, psychosis, substance use, cognitive behavioral therapy, mindfulness, 
group interventions
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A DEFINITION OF TERMS 
Dual Diagnosis 
While the term dual diagnosis can be used to describe a range of co-occurring symptom 
presentations, for the purpose of this review it is limited to a substance use diagnosis occurring 
alongside an independent axis I psychotic disorder. 
Substance Use Disorders 
 Substance Use Disorders as a category consist of diagnoses of Substance Abuse and 
Substance Dependence, which can be applied across all classes of substances, excluding 
caffeine.  Substance Abuse diagnoses are appropriate for individuals who demonstrate a 
maladaptive pattern of substance use leading to clinically significant impairment or distress in 
fulfillment of role obligations, or recurrent use in situations that are physically hazardous or 
result in legal, social, or interpersonal problems.  While individuals with these criteria incur 
harmful consequences for their pattern of use, there is not a presence of withdrawal or tolerance.  
An individual progresses to a diagnosis of Substance Dependence if symptoms of withdrawal or 
tolerance are present, or if they display a pattern of compulsive use despite attempts to abstain or 
reduce use (Diagnostic and Statistical Manual of Mental Disorders [DSM-IV-TR]; American 
Psychiatric Association, 2000).  In a study using a large national sample from the United States, 
26.6% of respondents reported a lifetime prevalence of substance use or dependence (Kessler et 
al., 1994).   
Psychotic Disorders 
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As diagnoses like schizophrenia and schizoaffective disorder account for a wide range of 
symptoms, some researchers argue that current conceptualizations operate from a top down 
approach, which is reductionistic and lumps distinct symptoms (hallucinations, delusions, 
paranoia) into one category rather than fully conceptualizing their distinctive mechanisms and 
integrated presentations (Bentall, Jackson, & Pilgrim, 1988).  For the purposes of this review, the 
treatment of psychotic disorders will be discussed as a diagnostic category, with the recognition 
that there is variability between disorders.  Within the DSM-IV-TR, schizophrenia and other 
psychotic disorders are broadly categorized together as differential disorders containing 
psychotic symptoms as a prominent aspect of their presentation (American Psychiatric 
Association, 2000).  This category includes Schizophrenia, Schizophreniform Disorder, 
Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic 
Disorder, Psychotic Disorder Due to a General Medical Condition, Substance Induced Psychotic 
Disorder, and Psychotic Disorder Not Otherwise Specified.  The specific definition of the word 
psychosis has not been universally accepted and refers to different constellations of positive 
symptoms even between disorders in this category.   
Psychotic disorders as a whole have a lifetime prevalence estimated at 3.06% (Perala et 
al., 2007).  Of this diagnostic category, schizophrenia has the highest rates of prevalence, which 
has been estimated at 0.5% to 1.5% (DSM-IV; American Psychiatric Association, 2000).  
Symptoms of Schizophrenia include the presence of positive (psychotic) symptoms to include 
delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior; and 
negative symptoms (including affective flattening, alogia, or avolition).  Typically positive 
symptoms reflect distortion or excess of normal functions, while negative symptoms show 
diminishment or loss of normal functions (DSM-IV; American Psychiatric Association, 2000).  
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For a schizophrenia diagnosis, two of the aforementioned symptoms must be present 
continuously for at least 6 months, with significant impairment in social or occupational 
functioning.   
INTRODUCTION 
The evolving nature of psychology becomes painfully evident when looking at the 
treatment of psychotic disorders.  Conceptualization and treatment for psychosis has undergone 
dramatic phases of change, and is again at another threshold of innovation.  Early treatment of 
psychosis is marked with inhumane and extreme procedures, along with a sense of threat and 
mystery surrounding symptoms.  In many cultures psychosis has been associated with moral 
failings or supernatural forces, which has created a sense of fear and stigma towards individuals 
with these disorders and their families (Phelan, Bromet, & Link 1998).  In the 18th century 
asylums were introduced as a solution to the problem of mental illness, though reformers would 
later regard these institutions as harsh, overcrowded, and engaging in practices that constituted 
abuse or neglect (Rosenblatt, 1984).   
In spite of these concerns, institutionalization of the mentally ill became increasingly 
common, and at the turn of the 19th century, nearly 150,000 patients with psychosis were 
confined in asylums in the United States alone (Shorter, 1997).  There was often a pessimistic 
view of treatment outcomes, as psychosis was considered to be an early manifestation of 
dementia.  Although there was recognition of the biological origin of the disorder, a lack of 
technology left a great deal of mystery surrounding symptoms.  As such, hospital stays were 
often long-term, and many patients spent their entire lives in asylums without recovering or 
being discharged (Sanbrook & Harris, 2003).  The word psychosis was established in 1845 as an 
alternative to the word madness, and in some circles, greater momentum began to build towards 
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identifying and classifying symptoms (Beer, 1995).  By the mid 20th century, hospitalization 
rates were recorded to have reached 500,000 in the United States, however these numbers began 
to decrease as evidence-based practices became more readily available (US National Library of 
Medicine, 2011).   
In 1952 the first antipsychotic medications were introduced to the public (Bennett, 1998), 
which aligned with a movement to deinstitutionalize care and move individuals into community 
care and home placements.  Despite innovations in treatment, leading researchers in the 20th 
century maintained that psychosis or madness should be distinguished from affective illnesses 
(Jaspers, 1963).  This distinction created a sense of otherness, and essentially classified psychotic 
disorders as a phenomenon distinct from general psychology.  While this sense of otherness is in 
many ways pervasive in the field, there has been a steady evolution building in the 
conceptualization and treatment of psychotic disorders.  
Treatment of patients with psychosis has shifted dramatically in response to evolving 
theoretical understandings of these disorders.  Asylums equipped with steel restraints and 
experimental surgeries seem unconceivable today.  As researchers and clinicians began to 
understand psychotic disorders as biological in origin, developments in pharmacology targeted 
the neurobiological source, treating positive and negative clusters of symptoms.  But this was 
only the first step in the direction of holistic care.  The field continues to shift and grow, and is 
on the brink of yet another revolution in the treatment of psychotic disorders, one that includes 
the highly prevalent rates of comorbid substance use disorders, termed dual diagnoses.  In this 
thesis, current innovations in the treatment of psychosis and substance use disorders are reviewed 
independently, showing a natural convergence of mindfulness-based interventions for the 
treatment of dually diagnosed clients. 
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METHODS 
 A total of 196 sources were utilized for this literature review.  These included theoretical 
papers, treatment manuals, meta-analyses, qualitative studies, quantitative studies, book chapters, 
and discipline-specific reference books including the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV-TR; American Psychiatric Association, 2000).  Research articles 
were collected through online databases including PsychINFO and Web of Science.  Articles 
were obtained by entering the following keyword search topics: dual diagnosis, psychosis, 
schizophrenia, substance use, mindfulness, MBRP, and cognitive behavior therapy.  International 
publications were included, particularly articles from the United Kingdom as a great deal of 
research about cognitive behavioral therapy for psychosis has originated out of the UK.  In 
addition to written sources, the author attended an intensive training for Mindfulness Based 
Relapse Prevention (MBRP) conducted by the creators of the intervention, and content from this 
training informed the following review. 
RESULTS 
Within the current clinical framework, symptoms of psychotic disorders are managed and 
medicated, but the broader roles of affect, cognition, and emotion are largely absent in treatment.  
Through a mode of symptom reduction, clients are often provided adjunctive treatment for social 
skills and family education (Mueser, Bond, & Drake, 2000), but psychosocial interventions 
beyond this are commonly overlooked.  This gap in psychosocial treatment can be felt, and there 
are limitations in psychopharmacological interventions when measuring functional improvement 
(Juckel & Morosini 2008; Lieberman et al., 2005).  Up to 50% of individuals who are medication 
compliant continue to experience ongoing positive and negative symptoms (Conley & Buchanan, 
1997).  In response to these limitations, the field is again undergoing a theoretical shift in 
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understanding psychotic disorders, and researchers and psychological professionals have begun 
to investigate symptoms from beneath the same biopsychosocial lens that has informed standards 
in the rest of the field. 
Psychosis as a part of the spectrum 
This transition sounds fairly simplistic, but is revolutionary.  Positive symptoms are no 
longer viewed as being outside of the realm of normal psychological functioning and a variety of 
theories explain the cognitive mechanics involved in psychosis.  A majority of researchers assert 
that cognitive theories are not stand alone explanations of these disorders (Garety, Kuipers, 
Fowler, Freeman & Bebbington, 2001).  Rather they compliment biological explanations of 
psychosis, and inform gaps in existing paradigms.  As neurobiological and cognitive theories are 
synthesized, richer explanations of psychosis emerge.  This fusion is described in a theoretical 
paper by Garety et al. (2007).  A neurodevelopmental model originally asserted by Weinberger 
(1987) continues to evolve based on improvements in technology and neuroimaging.  These 
models consider that brain lesions or abnormalities sustained early in life produce psychosis 
during the brains natural maturation process (Jones & Murray, 1991; Gogtay et al., 2011; 
Weinberger, 1987).  However the variability of symptom onset cannot be accounted for by 
neurological processes alone (Broome et al., 2005).  Researchers now suggest that while positive 
symptoms emerge as the result of dysregulation of the dopaminergic system, this biological 
process is also influenced by stressors in the environment (Howes et al., 2004; van Winkel, 
Stefanis & Myin-Germeys 2008; Walker, Curtis, Shaw, & Murray, 2002).  As dopamine begins 
to be fired independently, it creates aberrant experiences.  Delusions can be conceptualized as the 
mind trying to make sense of these anomalous experiences, a process which is informed by 
individual history and cognitive schemas (Kapur et al., 2005).  Adding social, cognitive, and 
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environmental factors to biological models enriches the formulation, and provides windows for 
intervention at the psychosocial level (Garety et al., 2007).   
Cognitive Schemas 
Individuals who are suffering from neurological impairments in attention, working 
memory, and executive function are more likely to experience stressful experiences in daily life.  
In fact, some studies suggest that impairments in these domains have the strongest association 
with experience of distress and quality of life appraisal for individuals with schizophrenia 
(Ritsner, 2007).  These stressful encounters open the door for the development of maladaptive 
beliefs, which are reinforced in future experience (Beck & Rector, 2005).  In addition to the 
stress associated with impaired functioning, the stigma regarding psychosis also contributes to 
negative illness appraisal, which impacts delusional distress (Watson et al., 2006).  Cognitive 
theorists continue to explore enduring beliefs that contribute to the clinical presentation of 
psychosis, and to examine these schemas independently of emotion.  A recent study found that 
defeatist beliefs served as mediators in the relationship between cognitive impairment and 
negative symptoms and functioning (Grant & Beck, 2009).  Similarly, asocial beliefs have been 
conceptualized as contributing to the social withdrawal seen in negative symptoms of psychosis 
(Grant & Beck, 2010). 
Negative schemas have a cyclical effect.  Dysfunctional beliefs often lead to future biases 
in cognitive processes and attributional styles, as well as heightened vulnerability for anxiety, 
depression, and paranoia (Fowler et al., 2006; Garety et al., 2007; Smith et al., 2006).  
Independent of depressed mood, negative self-concept has been found to be associated with more 
severe psychotic symptoms (Barrowclough et al., 2003).  Although resolving maladaptive belief 
patterns does not directly parallel the treatment process for disorders like anxiety and depression, 
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adjustments to schemas appear to influence ratings of quality of life for individuals with 
psychosis (Gaynor et al., 2011; Moritz et al., 2011).  Even for clients lacking insight into their 
delusional patterns, cognitive therapy is thought to be effective in promoting gains towards 
functional goals (Perivoltiotis, Grant, & Beck, 2009).  When treating psychosis from a cognitive 
behavioral perspective, practitioners may consider the individual’s history at the time of their 
first episode to inform understanding of their current beliefs and perceptions (Rathod et al., 
2010).  
Environmental Factors 
Researchers propose that social adversity encountered early in life may make individuals 
more vulnerable to psychosis.  This association has long been a source of controversy, and 
researchers have searched to explain findings that trauma victims and certain minority, urban, 
and migrant populations have higher rates of psychosis (Cantor-Graae & Selten, 2005; Fearon et 
al., 2006; Kirkbride et al., 2006; McGrath, 2006).  This finding may be explained by a two-fold 
biosocial process.  While genes do contribute to rates of psychosis, researchers propose that 
exposure to prolonged experiences of ‘social defeat’ produces a sensitization in the mesolimbic 
dopamine system, which is similar to the dopamine reactivity seen in groups at risk for psychosis 
(Howes et al., 2004; Selten & Cantor-Graae, 2005).  Additionally, experiences of 
marginalization, trauma, and adversity contribute to the development of negative schematic 
models; which in turn influence rates of anxiety, depression, and appraisal of future events.  A 
study by Marcelis et al. (2004) showed that individuals with psychosis had an altered 
neurobiological response to metabolic stress that was different than their non-psychotic first 
degree relatives.  The authors propose that this suggests that dysregulation was illness-related 
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and a reflection of overstimulation with agonist drugs or an effect of repeated environmental 
stressors (Marcelis, Cavalier, Gielen, Delespaul, & Van Os, 2004).   
Similarly, environmental factors are large contributors in symptom maintenance.  Levels 
of criticism or emotional over-involvement by caretakers (also termed expressed emotion) are 
highly correlated to negative outcomes.  A 1998 meta-analysis of expressed emotion found it 
was significant predictor of relapse in schizophrenia, especially for patients with more chronic 
forms of the disorder (Butzlaff & Hooley, 1998).  Caretaker criticism has been found to 
contribute to anxiety in psychosis, but not to the levels of psychotic symptoms (Onwumere, 
Kuipers, Bebbington, & Dunn, 2009).  Yet, one must consider the delicate interplay between 
affect and psychotic symptoms, and ways this cycle may be triggered by stressors in the 
environment.  More supportive environments have been found to correlate to better outcomes, as 
measured by lower re-hospitalization rates (Chien & Norman, 2009).  Researchers have reported 
that the social, cultural, and developmental contexts of psychotic symptoms seem to be the most 
related to actual impairment and dysfunction (Stip & Letourneau, 2009).  This theory may 
account for the popularity and efficacy of family therapy, which was found in a recent meta-
analysis to be the superior treatment (Huxley, Rendall, & Sederer, 2000).  While the results of 
family therapy have been favorable, some studies have suggested that benefits are not maintained 
in the absence of ongoing therapy.  It appears that ongoing skills and problem solving are 
essential components of this intervention, and associated gains may be direct reflections of 
reduced environmental stress.  This growing research base supports that symptoms can be 
impacted from environmental access points, and that providing tools for coping with the 
environment may lead to more positive outcomes in symptom management. 
Reasoning and attributional biases 
MBRP FOR DUAL DIAGNOSIS  10 
 
 
  In a comprehensive model of psychosis, Garety et al. (2001) proposed that in addition to 
dysfunctional schemas and adverse environments, anomalous experiences are transformed into 
positive symptoms through the application of reasoning and attributional biases.  The reasoning 
and attributional biases associated with psychosis involve the same processes observed in the 
general population.  A prominent example is confirmatory bias, a process in which individuals 
maintain strongly held beliefs despite contradictory evidence (Freeman, Pugh, & Garety, 2008).  
This bias can be observed in delusional persistence, as individuals view information that 
disconfirms their beliefs with less impartiality (Kuipers et al., 2006).  In addition, it has been 
found that individuals with psychosis often use less evidence in the process of decision making.  
This reasoning bias has been termed “jumping to conclusions,” and appears to contribute to 
delusional conviction, belief inflexibility, and the inability to generate alternative explanations 
(Garety & Hemsley, 1994; Garety et al., 2005). Individuals with persecutory delusions give 
greater attention to threatening stimuli, which maintains these strongly held beliefs.  These biases 
may become particularly salient in crises, as individuals in acute phases of psychosis report 
higher levels of catastrophic misinterpretation and beliefs of responsibility (Luzón, Harrop & 
Nolan, 2009).   
As anomalous experiences are unfamiliar and often perceived as foreign to previous 
modes of functioning, individuals may externalize the stimuli and reason that it is generated from 
outside of the self.  This externalizing appraisal is a key component in psychosis.  If an 
individual is able to acknowledge that the anomalous experience in being generated from the 
mind as a result of neurological symptoms, it changes the course of psychotic symptom 
presentation (Garety et al., 2001).  Misattributions often lead to views of an experience as 
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threatening or personally meaningful, which contributes to levels of distress, and in the view of 
cognitive researchers, shifts the experience into a clinical range. 
Appraisal 
Many cognitive researchers argue that psychotic experiences exist along a continuum, 
and that these experiences do not meet threshold as symptoms in and of themselves (Claridge, 
1997; Strauss, 1969; van Os et al., 1999).  To illustrate this spectrum, studies have presented 
cases of psychotic experiences in non-clinical populations (Brett et al., 2009; Johns et al., 2004).  
These experiences are in fact normalized in some cultures and subcultures (such as religion), and 
differences in clinical and non-clinical individuals are strongly associated not with symptoms, 
but with the levels of distress related to them.  Researchers have argued that much of difference 
between the reported levels of distress rests upon individual and community appraisal of 
symptoms.   
Similarly, Morrison (2001) formulated a cognitive theory of psychosis asserting that 
positive symptoms can be understood as intrusions, which become problematic due to 
interpretation of the content, or beliefs about the metacognitive process.  Brett et al. (2007) found 
a relationship between maladaptive metacognitive beliefs in the context of anomalous 
experiences and the need for care when comparing a clinical sample to individuals in the general 
population who reported psychotic-like symptoms.  Similarly to other cognitive theories of 
psychosis and appraisal (Chadwick & Birchwood, 1994; Garety et al., 2007; Morrison, 2001), 
individuals in the clinical sample appraised their experiences as more dangerous and negative, 
and were more distressed by them.  In a replication study, Lovatt et al. (2010) found that need for 
care was related to specific styles of appraisal, such as personalizing (appraising experiences to 
have been caused by others) or externalizing (appraising the experience to be generated from 
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outside the self).  As both the clinical and non-clinical sample in this study presented with high 
rates of trauma, the authors acknowledged that trauma may be related to the development of 
anomalous experiences.  They proposed however that appraisal may better explain the well 
established relationship between trauma history and the development of psychosis. 
In a review of literature involving the cognitive model of auditory hallucinations, 
Mawson et al. (2009) found that certain appraisals appeared to be linked to higher levels of 
distress in individuals hearing voices.  When the voices were appraised as malevolent, as being 
high in supremacy, of being of personal acquaintance, and when the individual appraised the 
voices with an attitude of disapproval and rejection; there appeared to be higher rates of distress.  
The authors suggested that social schemata may be a mediating variable in this relationship, and 
a possible target point for future interventions (Mawson, Cohen, & Berry, 2009). 
Affect 
Understanding the strong biological component in psychosis, cognitive behavioral 
clinicians often create mini-formulations of symptom maintenance (Tai & Turkington, 2009).  In 
these formulations the role of affect is strongly considered, as anxiety and depression are thought 
to trigger hallucinations (Freeman & Garety, 2003).  While in the general population stressful 
events trigger mood and anxiety symptoms, these triggers have additional significance for 
individuals with psychotic disorders, as anxiety and negative mood states often cascade into 
psychotic symptoms.  Researchers have found that higher levels of depression and lower self 
esteem are related to greater severity of auditory hallucinations, with more intensely negative 
content and greater associated levels of distress (Smith et al., 2006).  For individuals who 
experience auditory hallucinations, the presence of negative emotion is significantly correlated 
with the belief that voices are real (Garrett & Silva, 2003).  Speech output and language 
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disturbances of schizophrenia are also found to increase with exposure to negative emotion 
(Minor & Cohen, 2010; Minor et al., 2011, Seghers & Doherty 2009).  This phenomenon, termed 
affective reactivity, has been found to have greater prevalence in individuals with higher rates of 
depression (Phillips, Voglamier, & Deldin, 2007).   
Similar to the mechanisms in anxiety disorders, individuals with psychosis have been 
found to report higher levels of anxiety sensitivity and obsessional beliefs (Luzon, Harrop & 
Nolan, 2009).  Anxiety is thought to be the closest corollary to many symptoms of psychosis, 
and has been related to the paranoia observed in persecutory delusions (Freeman et al., 2002).  
Due to these perceived similarities, prominent anxiety theories have been applied to psychosis in 
exploratory studies. Seghers and Doherty (2009) found that baseline depression and sensitivity to 
stress was related to affective reactivity, independent of baseline neurocognitive impairments.  
While this patient population as a whole has been found to have higher rates of reactivity, there 
appears to be variable levels of vulnerability to psychotic relapse in response to stress (Docherty, 
St-Hilaire, Aakre, & Seghers, 2009).  These findings inform the stress diathesis model of 
psychotic symptom formation, and provide yet another access point for relapse prevention. 
Avoidance Strategies 
 Negative symptoms may be understood as contributing to avoidance of feared stimuli, 
which add to the client’s inability to confront and learn new information to counter their beliefs. 
The use of avoidance strategies to control internal experiences can often predict functional 
impairment in the general population (Hayes et al., 1999) and have been found to be related to 
delusional persistence in psychosis (Freeman & Garety, 2003; Lobban, Barrowclough & Jones 
2004). Freeman, Garety, and Kuipers (2001) found that 96% of a sample of individuals with 
persecutory delusions reported to have utilized safety-behaviors over the preceding month.  
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Greater use was positively correlated with more distressing delusions (Freeman, Garety, & 
Kuipers, 2001).  While individuals often report utilizing these strategies to reduce symptom-
related distress, avoidance has been found to contribute to positive symptom maintenance.  
Individuals with psychosis who suppress or avoid unwanted thoughts are significantly more 
likely to experience distressing delusions when exposed to daily stressors (Goldstone, Farhall, & 
Ong, 2011).  Avoidant safety behaviors and punishment-based thought control strategies have 
been found to be associated with both the frequency of psychotic-like phenomenon and levels of 
distress (Cambell & Morrison, 2007).  Experiential avoidance  can be considered as a reaction to 
the judgment and discomfort of psychotic experiences that pulls the individual further into the 
reaction and farther away from the self (Chadwick, Taylor, & Abba, 2005).   
Treatment Implications 
When reviewing the literature it becomes apparent that levels of distress fluctuate in 
relation to factors of cognition, affect, and environment; even when positive symptoms remain 
constant.  Based on these theories of symptom maintenance, cognitive behavioral techniques are 
highly adaptive adjunct treatments to pharmacological interventions, and can provide a 
framework for monitoring mood states, thought patterns, and the environmental stressors that 
directly impact symptom severity and distress.  Wykes et al. (2007) conducted a meta-analysis to 
clarify the benefits of CBT for psychosis.  When reviewing 34 independent trials the authors 
detected an overall beneficial effect size of 0.40 for the target symptom.  Additionally, 
significant effects ranging from 0.35 to 0.44 were detected for positive symptoms, negative 
symptoms, functioning, mood, and social anxiety.  Benefits of the treatment appeared to 
generalize, as improvements between domains were found to be related to improvements in 
others (Wykes et al., 2007).  The application of cognitive behavioral therapy has clear benefits in 
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the treatment of psychotic disorders, and may be a stepping stone towards more comprehensive 
models of care.  
Mindfulness for Psychosis 
 Cognitive theory spurred an evolution in the conceptualization of psychosis.  This energy 
ignited new waves of research in the field, and continues to propel innovation in treatment.  As 
emerging theory meets clinical practice, interventions often require modifications to adapt to 
symptoms as they present in the field.  When applying traditional CBT to psychosis, there is a 
clear distinction from disorders like depression and anxiety.  Psychosis is often considered to be 
a chronic condition, and interventions must provide flexible models for coping with biological 
symptoms that are not ameliorated through medication.  Shifts from traditional CBT become 
more appropriate when working with organic parts of psychotic disorder presentations which are 
more stable or enduring.  In stretching and adapting, many applications of CBT have morphed 
into frameworks that consider chronic symptomology, and promote a natural sense of curiosity 
and acceptance of internal processes.   
In studies of individuals with psychosis, efforts to suppress or control psychotic 
symptoms have been found to lead to negative outcomes and increased frequency of unwanted 
thought content (Salkovskis & Campbell, 1994; Wegner, Schneider, Carter, & White, 1987).  It 
therefore seems counterintuitive to utilize these same techniques in psychological interventions, 
and researchers have shifted treatment models to instead focus on reducing the distress related to 
psychotic symptoms (Birchwood, 2003; Chadwick, Birchwood & Trawler, 1996; Steel et al., 
2007).  Some research suggests that the cultivation of mindfulness skills may mediate treatment 
response in traditional CBT (Gaudiano, 2005).  This may explain the results of a recent mediator 
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analysis of CBT for psychosis in which the hypothesized mediators (cognitive schemas, insight, 
and reasoning) were not found to be related to the positive outcomes of the intervention.  An 
alternate mechanism appeared to lead to reduction in depression as well as positive effects 
observed on social functioning and delusional distress (Garety et al., 2008).  As the research base 
of CBT for psychosis continues to build, interventions adjust to capitalize on the most prominent 
mechanisms of change, which may be rooted in awareness and acceptance.  
Mindfulness based interventions deemphasize the focus on cognitive change techniques, 
and cast an emphasis on awareness and acceptance of internal events.  While the target is not 
specifically a reduction in psychotic symptoms, they are often impacted by changes in 
acceptance and affect.  For instance, in a recent study greater acceptance of voices was 
associated with lower levels of depression, increased confidence in coping with command 
hallucinations, and greater subjective quality of life (Shawyer et al., 2007).  Awareness of 
symptoms is thought to disrupt the cycle of experiential avoidance which often maintains 
psychotic symptoms (Chadwick, 2006).  Based on these findings, treatment goals shift from 
symptom reduction and instead gravitate towards increased awareness and acceptance of 
psychotic sensations.  As the treatment is focused on relationship to symptoms rather than the 
symptoms themselves, clients are encouraged to let psychotic experiences pass by without 
getting pulled in.  
Review of Mindfulness-Based Interventions for Psychosis 
ACT for psychosis. 
Pilot study. 
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In 2002, Bach and Hayes published an article describing a novel use of a brief acceptance 
and commitment therapy (ACT) for psychotic inpatient clients.  Their sample consisted of 80 
individuals who were randomly assigned to a treatment as usual (TAU) group or an experimental 
ACT group while receiving acute hospital services.  Individuals in the experimental ACT 
condition received 4 individual sessions that were 40-50 minutes in length.  The content of the 
ACT intervention was drawn from the ACT manual, with metaphors tailored to fit the population 
including “taking the brain for a walk” and a metaphor about trying not to appear anxious when 
taking a lie detector test.  Results were measured using re-hospitalization data and a scale 
measuring the frequency of delusions or hallucinations over the previous month.  Additionally, 
distress and believability of symptoms and medication compliance were measured through self 
report (which was confirmed in 40% of cases by primary care givers, laboratories, or medical 
records).   
Individuals who participated in the experimental ACT group were found to have a 50% 
reduced rate of hospitalization over a 4-month period.  Participants were more likely to report 
their symptoms than individuals in the TAU group, and were three times more likely to stay out 
of the hospital if they did so.  Data indicated that individuals in the ACT group reported similar 
symptom frequency and distress, but lower believability of symptoms than the TAU participants.  
Although the effects appeared to be significant, they did not maintain over time.  The authors 
suggest that this may be due to the brief nature of this intervention, and concluded that future 
research should focus on extending the intervention and integrating it into existing evidence 
based packages for psychosis. 
Replication study. 
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Building upon the success of the pilot study of ACT for psychosis and controlling for 
some of the methodological limitations of the 2002 study, Gaudiano and Herbert (2006) 
conducted a replication study with a population of 40 adults in a university-based hospital.  All 
participants were hospitalized at the time of the study and presented with psychotic symptoms 
and a diagnosis of a psychotic disorder or another psychiatric diagnosis with psychotic 
symptoms that required hospitalization.  Individuals who agreed to participate in the study were 
randomly assigned to the ACT group or enhanced treatment as usual (ETAU).  To control for the 
additional client contact in the ACT condition, Gaudiano and Herbert enhanced the treatment as 
usual group, and the resulting ETAU group consisted of psychopharmocology, case 
management, and psychotherapy.  The ACT group followed the same format as the intervention 
conducted by Bach and Hayes (2002).  Participants received an average of 3 sessions that were 1 
hour in length.    
Progress was measured using the Brief Psychiatric Rating Scale (BPRS), Clinical Global 
Impressions Scale (CGI), self-ratings of psychotic symptoms, and the Sheehan Disability Scale 
(SDS).  Measures were taken pre and post intervention, and re-hospitalization data was collected 
4-months post intervention.  Consistent with the findings of Bach and Hayes, the ACT group 
showed a 50% reduction in re-hospitalizations compared to the TAU group at 4 month follow-up 
(28% vs. 45%).  Although this finding was of note, it did not reach clinical significance.  The 
authors proposed that this may be a limitation of small sample size.  Additionally, individuals in 
the ACT group showed superior improvement in measures of affective severity, global 
improvement, distress associated with hallucinations, and social functioning.  Individuals in the 
ACT group showed a reduction in the believability of hallucinations that was not present in the 
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ETAU group when controlling for changes in the frequency of hallucinations.  Change in 
believability was strongly associated with change in distress (Gaudiano & Herbert, 2006). 
To gain further insight into the mechanisms of change, Gauidiano et al. (2010) utilized 
this 2006 data in a mediation analyses.  The results supported that hallucination frequency did 
not mediate the outcome of distress, and rather this relationship was mediated by the 
believability of hallucinations.  The analysis suggested that 68% of the variance of the effect of 
treatment on distress outcomes could be explained by hallucination believability post treatment 
(Gaudiano, Herbert, & Hayes, 2010).  This finding supports the theory of change in acceptance 
based interventions, and the positive potential of teaching cognitive flexibility to cope with 
positive symptoms. 
Yoga therapy add-on treatment. 
Duraiswamy et al. (2007) proposed that as an add-on therapy, yoga could benefit clients 
with schizophrenia by improving psychopathology, quality of life, and social functioning.  Sixty 
one clients with a diagnosis of schizophrenia were recruited from in-patient and out-patient 
services of the National Institute of Mental Health Sciences in Bangalore India.  Participants 
were on stable antipsychotic medication regimens at least 4 weeks prior to the start of the 
intervention and throughout the 4 month study, and were randomly assigned to a physical 
training (PT) or yoga therapy (YT) group.  The authors utilized the Positive And Negative 
Syndrome Scale of Schizophrenia (PANSS) to measure outcomes of psychopathology, and social 
and occupational improvements were measured using the Social and Occupational Functioning 
Scale (SOFS).  Quality of life was measured using the WHO Quality of Life BREF Version, 
WHOQOL-BREF.  Side effects were assessed by the Simpson Angus Scale for Extrapyramidal 
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Symptoms and the Abnormal Involuntary Movement Scale (AIMS).  Assessments were 
administered pre and post intervention.  Both groups showed significant drops in PANNS and 
SOFS scores post intervention.  However, only the YT group had statistically significant 
improvements in quality of life after controlling for effects of baseline ratings, with moderate to 
large effect sizes.  Differences were also detected in the YT group in areas of the PANNS, 
including significant reductions in symptom dimensions and total score compared to the PT 
group.  The authors proposed that future research could investigate the benefits of yoga for 
individuals with schizophrenia to explore effects on cognitive function, stress reduction, and the 
physical health conditions associated with antipsychotic medication (Duraiswamy et al., 2007). 
Mindfulness group. 
  Chadwick et al. (2005) conducted a study of a group mindfulness intervention for 
individuals experiencing distressing psychosis including paranoid beliefs and hallucinations.  
Ten participants were selected from a pool of community referrals who reported distressing 
psychotic experiences lasting for a period of at least 2 years.  Participants received six 90-minute 
mindfulness groups in addition to standard psychiatric care and medication.  The focus of the 
intervention was helping participants establish a mindful relationship with unpleasant voices, 
images and paranoid thoughts.  The group facilitators provided exercises that taught mindfulness 
of the breath and awareness of the body.  Outcome was primarily measured using the Clinical 
Outcomes in Routine Evaluation (CORE) and Mindfulness Questionnaire.  At the end of the six 
week intervention, participants showed a significant drop in scores on the CORE (z=-2.655, 
p=.008).  Scores on the Mindfulness Questionnaire varied, but were found to have an overall 
increase of 42% post intervention.  Participant feedback appeared positive, and participants 
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reflected an understanding of accepting psychotic experience rather than trying to suppress or 
change it (Chadwick et al., 2005) 
Case studies of mindfulness for distressing voices. 
 Taylor et al. (2009) delivered a 12-week mindfulness intervention in two case studies, 
with the hypothesis that mindfulness training alone would reduce distress and conviction in 
beliefs associated with distressing voices.  Both clients were male and met criteria for paranoid 
schizophrenia with current auditory hallucinations.  Both expressed anxiety related to voices, and 
different experiences of anger, confusion, and negative mood.  Clients completed scales 
assessing distress and belief in what the voices were saying, which were collected both at the end 
of weekly sessions and while at home midweek.  Level of mindfulness was measured pre and 
post intervention with The Southampton Mindfulness of Voices Questionnaire (SMVQ).  
Weekly sessions were reflective of Chadwick’s (2006) approach, and lasted one hour.  They 
were comprised of two short mindfulness practices followed by Socratic inquiry.  Participants 
were provided with audio recordings to practice between sessions.  When plotting belief 
conviction and distress over time, there was no immediate change in outcome, but change 
became evident within 3 to 4 weeks.  Cognition and affect were observed to change at the same 
time, with fluctuations within participants.  Both clients showed an increase on the SMVQ post 
treatment.  The first participant’s score fell within 2 SDs of the mean for outpatient clinical 
population and the second participant’s score fell 2 SDs above the group mean by the end of the 
program.  Both participants reported feeling less overwhelmed by their experiences and more 
assured in their ability live with the voices.  The authors suggest that these findings support that 
mindfulness is a cognitive and affective change agent, and may be preferable to traditional CBT 
strategies in working with distressing auditory hallucinations.  This study was limited by lack of 
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symptom based measures and the inability to generalize finding beyond the two clients involved 
in the study, but has promising clinical implications. 
Mindfulness training for anxiety in schizophrenia. 
Davis et al. (2007) integrated curricula from MBSR and MBCT to create an 8-week 
mindfulness program targeting anxiety and stress associated with schizophrenia and developing 
self-compassion.  Their sample consisted of 5 outpatient clients in post-acute phases of 
schizophrenia or schizoaffective disorder.  The authors proposed that MBSR has already been 
used to treat anxiety in chronic conditions, and could be extended to treat the high levels of 
anxiety and stress that are associated with disorders like schizophrenia.  As the researchers were 
in the development stage of the intervention, they collected participant self reports and clinician 
reports as outcome data.  Clients and clinicians did not report an increase in the incidence of 
delusions or hallucinations and on average clients attended 88% of the group sessions.  
Participant feedback was generally positive, and group members reported the development of 
new coping skills, increased awareness and acceptance, and improvements in negative symptoms 
and thought patterns. 
Participant perspectives on mindfulness meditation training. 
Throughout the literature, there have been general concerns that meditation or mindfulness 
practice could negatively impact individuals with psychosis and lead to increases in symptoms 
and distress.  To assess these concerns, Brown et al. (2010) collected qualitative data from a pilot 
study of an adapted an 8-week MBSR program targeting anxiety related distress in 
schizophrenia.  The authors’ goal was to assess the feasibility and acceptability of using this 
approach to assess if the program met the participant’s expectations, and to collect general data 
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about response to the intervention and impact of mindfulness exercises on positive symptoms.  
The sample consisted of 15 men with a diagnosis of schizophrenia or schizoaffective disorder, as 
confirmed by the DSM-IV criteria and administration of the Structured Clinical Interview for the 
DSM-IV (SCID). A grounded theory approach with multiple outside raters was used to analyze 
the data.  The prominent themes that emerged for positive outcomes included cognitive changes, 
group support, present focus, relaxation, self awareness/acceptance, and symptom reduction.  
Few participants identified negative outcomes, and those that were identified appeared to relate 
to sad memories and feelings, rather than increase in positive symptoms.  Participants appeared 
to have either a neutral response about positive symptoms during meditations (they were no 
worse than in general) or positive feedback about using mindfulness to stabilize in the presence 
of positive symptoms.  In fact, relief from psychiatric symptoms was identified most often as the 
largest benefit of the program, followed by relaxation.  These findings suggest that mindfulness 
may be an appropriate intervention for use in this population.  Although this study was 
conducted with a small sample, it establishes important data about the impact of mindfulness-
based interventions on participants with psychosis (Brown et al., 2010). 
Defining This Phase of Evolution in Treatment  
The integration of mindfulness based interventions has captured momentum long building in 
the treatment of psychosis, and is carrying innovation forward.  The field has moved far beyond 
the fear and mystery that once overshadowed the phenomenon of psychosis.  It has progressed 
beyond purely biological models, and continues to broaden understanding of these disorders.  
While symptom reduction techniques often require a restriction of lens, mindfulness-based 
interventions remove the lens entirely.  They are able to capture a larger array of symptom 
presentation because the focus of treatment takes place at a broader, metacognitive level.  This is 
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ideal in the treatment of psychosis, as there are tremendous rates of comorbidity associated with 
these diagnoses.   
 “Co- Occurring” Disorders 
 
Psychotic disorders have long been associated with heightened rates of commorbidity 
relative to other DSM primary diagnoses (Green, Canuso, Brenner & Wijcik, 2003; Pincus & 
Tew, 2004).  Rarely does this population present with symptoms that would warrant a single 
diagnosis, and there is often a complex web of interrelated symptoms to untangle.  In a meta-
analysis, Buckley, Miller, Leher, and Castle (2008) calculated average prevalence rates based on 
previous studies of comorbid mood and anxiety disorders in individuals with schizophrenia.  
They found that 50% of individuals with schizophrenia also presented with clinical depression, 
29% with posttraumatic stress disorder, 15% with panic disorder, and 25% with obsessive-
compulsive disorder (Buckley et al., 2008).  Other studies have presented similar findings, which 
raise questions about the current conceptualization of psychotic disorders (Cassano et al., 2000).  
It has been argued that the high degree of symptom overlap shows that current constructs are 
overly simplistic, and that psychotic disorders may be a “failed” diagnostic category (Bentall, 
2006).  Other theorists propose that the great variability in positive and negative symptoms 
suggest that these disorders would be better described as a group of diseases that share common 
expression but are the result of different etiology (Kirkpatrick, Buchanan, Ross, & Carpenter, 
2001).  Regardless of the theoretical underpinnings of comorbid disorders in this population, 
consideration of overlapping symptoms is an important factor in delivering quality care.  
Co-Occurring Substance Use Disorders 
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While untreated mood and anxiety disorders can have profound effects on individuals 
with psychotic disorders, comorbid disorders related to substance use are particularly impactful.  
Up to 50% of individuals with a psychotic disorder also meet criteria for a substance use disorder 
at some point in their lifetime (Barbee et al., 1989; Drake & Wallach, 1989; Mueser et al, 1990; 
Negrete et al., 1986, Richard et al., 1985).  Researchers have found that this heightened 
vulnerability can be observed both before and after the onset of psychotic symptoms (Hambrecht 
& Hafner, 1996).  Problematic substance use is found to occur at a rate 4.6 times higher than that 
of the general population (Dixon, 1999).  Many theories have been proposed to account for these 
inflated rates, which address a variety of biopsychosocial factors.  While it is assumed that much 
of the dual vulnerability is related to neurological deficits, there are also common impairments in 
vocational, social, and educational domains that are common risk factors for developing a 
substance use disorder (Drake, Wallach, Alverson, & Mueser, 2002).  It is therefore suggested 
that social and environmental deficits may place individuals in this population at greater risk for 
problematic substance use.  
In comparison to the general substance abusing population, individuals with both a 
psychotic disorder and a substance use disorder are more likely to be males with lower levels of 
education and a family history of substance use (Barnes et al., 2006; Cantwell, 2003; Kavanagh 
et al., 2004).  Yet, some have suggested that rates of substance use in women with a psychotic 
disorder are underreported, as they are more likely to receive services for mental health than 
substance use (Alexander, 1996).  Better premorbid functioning has also been found to be 
associated with higher rates of substance use.  This has been explained by social theory, as the 
capacity to procure drugs and alcohol is related to social ability and overall functioning (Carey, 
Carey, & Simons, 2003; Dixon, Haas, Weiden, & Frances, 1991; Sevy et al., 2001).  In the 
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dually diagnosed population, alcohol has been found to have higher rates of use amongst older 
individuals, while drug users tended to be younger (Salyers & Meuser, 2001). In parallel to the 
general population, substance use typically remits with age (Dixon, 1999).   
When tracking the developmental course of psychotic disorders, substance use is often 
associated with earlier onset of psychotic symptoms (Kovasznay et al., 1997, Mauri et al., 2006).  
These findings support theories that substance use, particularly the use of marijuana and 
amphetamines, may trigger the development or expression of underlying psychotic disorders 
(Cuffel, Heithoff, & Lawson, 1993; Degenhardt & Hall, 2001).  This association has been fairly 
controversial, and researchers have tried to clarify the relationship.  A research team in New 
Zealand found that while the majority of cannabis users do not develop schizophrenia, 
adolescents who possessed a faulty allele were more vulnerable (Caspi et al., 2005).  There is a 
tremendous amount of debate about the relationship between substance use and the development 
of primary psychotic disorders, and behavioral and biological research efforts continue to 
explore whether the relationship is causal or bidirectional (Gregg, Barrowclough & Haddock, 
2007).  
Dual Diagnosis 
Although studies suggest that the reasons for substance use in individuals with psychotic 
disorders are similar to those reported in the general population (Dixon et al., 2001), there are 
components of use and outcomes that are fundamentally different.  It has been suggested that a 
dysregulation of dopamine may predispose patients with schizophrenia to abuse drugs 
(Chambers, Bickel & Potenza, 2007; O’Daly, Guillin & Tsapakis, 2005).  While the types of 
substances used in this population appear to be reflective of community trends (Dixon, 1991), the 
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effects of substances are observed to be somewhat different (Mueser et al., 1995; Dixon et al., 
1990).  While current research does not support that substance use is an attempt to suppress 
psychotic symptoms (Brunette, Mueser, Xiie, & Drake, 1997; Dervaux, 2001; Gregg, 
Barrowclough & Haddock, 2007; Mueser et al., 1992; Regier et al., 1990), there does seem to be 
a relationship between substance use and attempts to alleviate dysphoria and cope with psychotic 
symptoms (Addington & Duchak, 1997; Baker et al., 2002 Dixon et al., 1991; Fowler et al., 
1998; Goswarni et al., 2004; Green et al., 2004; Schofield et al., 2006; Test et al., 1989; Warner 
et al., 1994). 
It would then appear that dually diagnosed individuals are not attempting to suppress 
positive symptoms through substance use per se, but rather trying to cope with the distress they 
experience regarding symptoms of their disorder.  This distinction opens up new considerations 
for treatment.  While certain interventions target symptom reduction, others target the 
metacognitive process surrounding the disorder.  While this is a relatively new area of research, 
initial findings suggest that negative appraisal of symptoms is related to risky behaviors, 
including suicide and increased alcohol intake (Fialko, Freeman & Bebbington, 2006).  This is 
consistent with CBT models, which assert that judgment about positive symptoms leads to 
avoidant behaviors, such as social withdrawal and self harm (Tai & Turkington, 2009).  
Acceptance and Commitment Therapy (ACT) describes a similar process as cognitive fusion, and 
asserts that when individuals fuse with their thoughts it often results in avoidance or withdrawal 
(Hayes & Strosahl, 2004; Hayes et al., 1999).  Substance use can be inserted into this model as a 
method of avoiding distress associated with positive symptoms, and dual diagnosis individuals 
often report using substances to cope with negative affect (Spencer et al., 2002).  Based on these 
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distinctions, conceptualizing substance use in this population may be a different process from 
that of the general population, and interventions must be modified accordingly.   
The rate of comorbid substance use is higher in inpatient settings, as clients are more 
likely to receive care when they present with two or more conditions (Mueser et al., 1995).  
However, despite the high prevalence of comorbid substance use observed in mental health 
settings, it has been found that dually diagnosed individuals are highly unlikely to receive 
treatment for both disorders (Epstein, Barker, Vorburger & Murtha, 2004).  Integrated care is 
tremendously important, as substance use has a significant impact upon symptom severity and 
outcomes.  Individuals with psychotic disorders who are using substances are found to have a 
greater number of psychotic symptoms (Negrete et al., 1986), more frequent rates and earlier 
psychotic relapse, and higher associated rates of re-hospitalization (Drake & Wallach, 1989; Hall 
et al., 1977, Schwartz & Goldfinger, 1981).  The addition of a substance use disorder amplifies 
vulnerability in an already at-risk population, and increases rates of victimization, as well as HIV 
and AIDS infection (Brunette, Mueser, & Drake, 2004).  Substance use has also been related to 
higher rates of treatment and medication noncompliance, which can be a mediator of psychotic 
symptoms (Drake 1989; Miner et al., 1997).  Psychopharmacological interventions are first-line 
treatment for individuals with a psychotic disorder, and medication noncompliance has been 
found to be eight times more likely for individuals who are diagnosed with a comorbid substance 
abuse disorder (Owen et al., 1996).   
The impact of substance use disorders is significant for individuals with a dual diagnosis, 
and it also has a strong impact on the community.  Contact with the legal system has been found 
to be increased with the addition of substance use (Abram & Teplin, 1991; Barry et al., 1996), as 
well as rates of violence and suicide (Barry et al., 1996; Drake et al., 1989; Dassori et al., 1990; 
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Fulwiler et al., 1997).  Individuals with dual diagnoses present with increased rates of 
homelessness and housing instability (Drake et al., 1991), medical problems (Brown, 1997; 
Felker et al., 1996), and greater associated costs due to hospitalizations and crisis-oriented care 
(Drake et al., 1991; Kivlahan et al., 1991; Shaner et al., 1995).  Focusing solely on a psychotic 
disorder at the expense of drug and alcohol treatment can result in compromised care and 
devastating long-term consequences. 
Dual Diagnosis Treatment 
Knowing these statistics and outcomes, it seems intuitive that integrated treatment would 
be the standard of care.  The fact that clients rarely receive concurrent treatment is therefore 
surprising, and raises important questions about this lack of services.  In the 1980s, integrative 
models of intervention were identified as being essential in the treatment of dually-diagnosed 
clients (Drake, O’Neal, & Wallach, 2008).  Such models have allowed organizations to manage 
care of both diagnoses under one roof.  Although integration has improved the overall system of 
care, there are no criteria as to what services should be provided in these settings.  No 
empirically supported treatments for dual diagnoses exist, and so practitioners are left to meld 
interventions without supportive guidelines (Drake et al., 2006).  Historically, patients with 
comorbid substance use disorders have been excluded from research, and so only recently have 
research efforts addressed the dually diagnosed.  Within this research, there has been 
considerable difficulty bridging the gap between standard drug abuse treatment and psychosocial 
interventions for psychotic disorders. These approaches are in many ways juxtaposed, as the 
supportive methods used to reduce anxiety in addressing psychotic symptoms seem to contrast 
the often confrontational approaches utilized in substance abuse programming (Hellerstein & 
Meehan, 1987; Kleber, 1988).   
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Practitioners can now draw from evidenced-based treatments, as the literature has begun 
to expand for experimental dual diagnosis interventions.  Thus far, the most promising results 
have been found for individual treatments comprised of motivational interviewing (MI) and 
cognitive behavioral therapy (CBT; Baker, Bucci, Lewin, Kay-Lambkin, Constable, & Carr, 
2006; Barrowclough, Haddock, & Tarrier, 2001; Haddock, Barrowclough, & Tarrier, 2003).  The 
results of these interventions have been celebrated, and yet many professionals voice that 
individual treatment is unrealistic for the current treatment climate.  While the developers of 
these interventions propose that the costs of individual treatment is balanced out by reduced 
utilization of acute services (Barrowclough, Haddock, & Tarrier, 2001), the majority of services 
are delivered in community mental health settings, where group interventions are often the most 
practical and cost-efficient approach.  This system of delivery has lead to a growing demand for 
manualized group dual-diagnosis interventions (Cleary et al., 2008).  In addition to the cost-
effectiveness of group interventions, these approaches have the benefit of providing a sense of 
group belonging and creating a venue for sharing information related to harm-reduction 
strategies (James et al., 2004).   
Research with dual diagnosis populations has involved significant challenges including 
high attrition rates, small sample sizes, and flawed methodology (Cleary, Hunt, Matheson, 
Siegfried, & Walter, 2008).  Despite these limitations, researchers have begun to test group 
treatment methods for dually diagnosed clients, and effective components are becoming clearer.   
Review of Dual Diagnosis Group Interventions  
James et al. (2004) evaluated the effectiveness of a manualized group intervention based 
upon stages of change and harm reduction for dual diagnosis clients.  A total of 63 participants 
(55 male, 18 female; mean age = 27.7 years) were recruited from three major community mental 
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health services in Western Australia.  An Axis I diagnosis of a non-organic psychotic disorder 
and current use of alcohol or illicit drugs were the study eligibility criteria.  All participants 
received standard community mental health services, including outpatient therapy and case 
management.  Individuals were randomly assigned to either the control group or an experimental 
group.  The control group received a 1-hour session of education about general drug use, 
consequences of use for people with a psychotic illness, and harm-minimization strategies.  The 
experimental group attended a dual diagnosis program that consisted of weekly group sessions 
tailored to each participant’s stage of change and reasons for drug use.  The group leader utilized 
peer support, motivational enhancement, harm minimization, and relapse prevention strategies.  
Scores on the Brief Psychotic Rating Scale (BPRS; Overall & Gorham, 1962) and self-reported 
Brief Symptom Inventory (BSI; Derogatis, 1983) showed that the experimental group had 
greater improvement at 3-month follow-up in psychopathology, drug abuse, need for medication, 
and hospital utilization as compared to the control group. 
MI techniques have been frequently utilized in group interventions for dual diagnosis 
clients, but no specific group adaptation was manualized until a study by Santa Ana, Wulfert, 
and Nietert (2007).  Due to the need for group-based interventions for community mental health 
settings, the authors created Group Motivational Interviewing (GMI).  They tested its efficacy on 
a sample of 101 inpatient clients (66 male, 38 female; mean age = 37.5 years) diagnosed with at 
least one current substance use disorder and a nonsubstance-related major Axis I disorder.  All 
participants received standard inpatient care and were randomly assigned to one of two 
structured 120-min group sessions: either the GMI group or the therapist attention activity 
control group (TAAC).  Motivational interviewing techniques were applied to the group 
sessions, and empathy, reflections, and individual autonomy were emphasized.  The GMI group 
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built a culture in which clients were encouraged to share personal views about treatment and to 
discuss ambivalence.  The authors found that members of the GMI group attended aftercare 
sessions at a higher rate than did the control group.  Although there was not a significant 
difference in illicit substance abstinence rates between groups at 1-month follow up, of the 
participants who did report drug use, those in the GMI group averaged fewer drug use days than 
the control group.  Similar trends were noted at 3-month follow up. 
Bellack, Bennett, Gearon, Brown, and Yang (2006) created an intervention for dual-
diagnosis clients that utilized MI with additional incentives and structure, which they called the 
Behavioral Treatment for Substance Abuse and Persistent Mental Illness (BTSAS) program.  A 
highly structured social learning intervention, BTSAS included motivational interviewing and 
social skills training with urine analysis contingency. Bellack et al. examined the efficacy of the 
BTSAS among a sample of 120 stabilized outpatients (76 male, 44 female, mean age =42.7 
years).  All individuals met DSM-IV-TR criteria for drug dependence and had severe and 
persistent mental illness (SPMI).  Participants were randomly assigned to either the BTSAS 
group or a control group representative of standard treatment at a university-based clinic that 
consisted of supportive treatment and didactic education about the effects of drugs.  Both 
treatments were administered twice weekly in small groups by trained healthcare professionals.  
Urinalysis was utilized at each session to monitor progress.  The authors found that BTSAS 
participants had a higher rate of retention and attended more sessions than did those in the 
control group.  The BTSAS group also had a higher proportion of clean urine tests during a 6-
month period relative to the control group, and significantly more participants in the BTSAS 
group than in the control group had at least one 4-week and 8-week block of continuous 
abstinence.  The BSTAS group showed small increases in reports of quality of life relative to the 
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control group and participants reported having more money for food and essential items than 
individuals in the control group.  The cost of services was offset by the cut in medical resources 
used by BTSAS participants post treatment. 
The Next Step 
Although promising research is emerging for the treatment of dual diagnosis clients, this 
is an area with tremendous opportunity for growth.  There is still a great need for novel 
treatments for this population, especially ones which integrate a common skill set.  Mindfulness 
and acceptance based approaches are ideal candidates, as new evidence suggests that these 
approaches are independently effective with both psychosis and substance use disorders.  
Mindfulness for Substance Use Disorders 
Relapse Prevention 
Just as mindfulness is on the cutting edge of research for psychosis, support is also 
beginning to emerge regarding the use of mindfulness-based interventions for substance use 
disorders.  Mindfulness practices are highly conducive with research coming out of the 
addictions field over the past 20 years, and are now the direct focus in the newest wave of 
treatment.  They are a natural fit to Relapse Prevention (RP: Marlatt & Gordon, 1985), a standard 
component of aftercare treatment for substance use, and are an integral part of the newest RP 
intervention.  Emerging from the cognitive behavioral model of addiction, RP has been found to 
be a highly effective model for preventing or limiting episodes of relapse for addictive behaviors 
and is one of the most widely disseminated adjunct treatments (Marlatt & Gordon, 1985; Parks & 
Marlatt, 1999; Irvin, Bowers, Dunn, & Wang, 1999).     
Initially proposed by Marlatt and colleagues (Marlatt & Gordon, 1985), the cognitive 
behavioral model of drug and alcohol relapse is based on progressive responses to high-risk 
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situations.  This model asserts that the use of effective coping strategies in high-risk situations 
enhances a sense of self-efficacy and decreases the likelihood of relapse.  In contrast, self-
efficacy declines when ineffective strategies are used, which changes individual perception of 
outcome expectancies and makes relapse more likely.  A key component of RP is the “abstinence 
violation effect,” which posits that attributions made about a lapse into drug or alcohol use have 
a strong impact on the likelihood of continued use and a full relapse into previous behavior 
(Marlatt, 1985).  If an individual views the lapse as something out of their control or a sign of 
personal failure, they are more likely to relapse into a pattern of previous use.  However, if the 
lapse is viewed as a small error or a learning opportunity, the individual is more likely to return 
to previous goals of abstinence.  This emphasis on appraisal parallels the language of acceptance 
and mindfulness-based interventions.  While outcome studies of RP have not shown increased 
rates of abstinence following substance use treatment, it has been found that RP significantly 
reduces the frequency and intensity of relapse episodes, essentially helping individuals to pull 
out of a relapse sooner (Marlatt & Donovan, 2005).     
RP interventions provide behavioral skills training along with cognitive interventions, 
which are implemented in the face of high-risk situations.  These situations are identified early in 
treatment, and clients are encouraged to be aware of environmental, physiological, interpersonal, 
and intrapersonal stimuli that may trigger relapse behaviors.  Common coping strategies include 
“urge-surfing,” which is a process of weakening addictive conditioning during experiences of 
cognitive urge or craving through non-action.  This process was initially based on Buddhist 
principles of right conduct, and utilizes cognitive strategies as well as behavioral relaxation 
techniques.  Self-efficacy is built through repeated non-action in the face of urges, resulting in 
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shifts in outcome expectancies (Witkiewitz et al., 2005).  RP is suggested as a follow-up to first-
line treatments for drug and alcohol use, and is a common feature of aftercare programs.   
The addition of mindfulness 
In many ways mindfulness training is a natural extension of RP treatment, and deepens 
the mechanisms of change in this intervention.  Meditation was included in the first publication 
of RP as a cognitive coping strategy, meant to provide lifestyle balance and stress management 
(Marlatt & Gordon, 1985).  However over time it became apparent to RP creators that the 
benefits of meditation could be expanded beyond this initial capacity.  Mindfulness meditation is 
a metacognitive skill set which enhances the self-monitoring used in CBT.  Although the precise 
agent of change is not certain, a possible mechanism is the explicit focus on the present moment.  
Often in addictive processes, individuals focus on the anticipation of future use, or become 
caught in the shame and guilt associated with previous use.  The focus on the present moment 
compliments RP objectives of letting go of past substance use behavior and the expectancy 
associated with craving and use.   
Mindfulness techniques add a unique element of non-judgment and acceptance to the 
thought monitoring process, which can be especially beneficial to substance users and clients 
with other diagnoses that carry stigma.  It has been proposed that the de-centering effects of 
mindfulness may also impact association between the self and identity of substance use, which is 
often prominent in recovery from an addictive behavior.  It may also de-center the relationship 
between negative affect and thoughts about the self which trigger relapse.  Paired with greater 
awareness of reactive behavior, de-identification improves the likelihood of building self- 
efficacy and positive outcome expectancies. 
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At the heart of the intervention, mindfulness is proposed as a way to alter automaticity, 
and can be applied to substance users by creating a greater awareness of internal experiences 
including physical sensations and mood.  Noticing these cues may disrupt the automatic process 
of seeking out and consuming substances.  Mindfulness practice is suggested as an effective 
coping tool to detect and cope with high-risk situations, and with practice individuals may be 
more able to process situational cues and become aware of reactive behaviors (Marlatt & 
Ostafin, 2006).  When in a high-risk situation, mindfulness practice provides a state of 
metacognitive awareness, and creates a wider lens to view the situation and make choices based 
on long term outcomes and goals (Bowen, Chawla, & Marlatt, 2011).  As the creators of RP 
became aware of the immense possibilities of mindfulness practice in the treatment of substance 
use, mindfulness- based relapse prevention (MBRP) emerged. 
MBRP Program 
MBRP is an 8-week aftercare program for addictive behavior which offers cognitive 
behavioral RP skills alongside experiential training in mindfulness meditation.  The group format 
and content were largely inspired by mindfulness based stress reduction (MBSR; Kabat-Zinn, 
1990) and mindfulness based cognitive therapy (MBCT; Segal, Williams, & Teasdale, 2002), but 
were adapted to address topics specific to addictive processes.  As participants are cultivating a 
mindfulness practice, the sessions build upon themes from previous weeks, and are therefore 
suggested as a closed rather than rolling group.  The program is designed to create moment-to-
moment awareness through direct experience.  After engaging in a mindfulness exercise, dual 
facilitators guide the group through Socratic inquiry.  A large focus of the group is increasing 
awareness of reactive or habitual behaviors, and developing a new relationship with these 
experiences based on compassion and acceptance.   
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The 8-week program includes the topics of automatic pilot and relapse, awareness of 
triggers and craving, mindfulness in daily life, mindfulness in high-risk situations, acceptance 
and skillful action, seeing thoughts as thoughts, self-care and lifestyle balance, and social support 
and continuing practice.  Home practice is assigned each week, and participants are supported in 
building practice in the first few weeks through audio-recorded guided meditations which 
include a body scan, breath meditation, mountain meditation, SOBER breathing space, urge 
surfing, sitting meditation, movement, silence with bells, and loving kindness meditation 
(Bowen, Chawla, & Marlatt, 2011).   
While mindfulness is fostered through exercises and individual practice, another key 
component of learning is the modeling provided by group facilitators.  There is tremendous 
potential in Socratic inquiry to demonstrate an attitude of gentle curiosity and non-judgment.  
Facilitators help to guide discussion to direct experience, rather than the judgment, story, or 
evaluation of that experience.  This is a language and skill set that is uncommon in our culture, 
and so must be intentionally cultivated by the facilitator before running a group.  This skill set is 
cultivated through mindfulness meditation, and therefore facilitators should have their own 
individual practice.  A foundation in mindfulness will be reflected through modeling, but can 
also be utilized to understand the experience of participants, which can often be one of 
frustration and overwhelm in response to becoming aware of the workings of the mind during 
meditation.  The expectation of personal practice makes mindfulness-based interventions distinct 
from traditional psychological interventions, and places a stronger demand on professionals who 
are interested in running these groups.  This investment however, appears to have tremendous 
potential, and initial findings suggest that mindfulness could be a powerful addition to traditional 
interventions for addictive behaviors. 
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MBRP Pilot Study 
Bowen et al. (2009) conducted an initial efficacy study of MBRP with a sample of 168 
adult participants recruited from a private nonprofit agency providing care for alcohol and drug 
use disorders.  To be eligible for the study, participants were required to have completed 
inpatient or outpatient treatment within the previous 2 weeks.  Participants were screened based 
on exclusion criteria of psychosis, dementia, imminent suicide risk, significant withdrawal risk, 
or need for more intensive treatment.  Reflective of agency demographics, the sample contained 
high levels of clients who were homeless (19% outpatient and 75% of inpatient) and had a 
history of involvement with the criminal justice system.  Eligible participants were randomly 
assigned to either the experimental MBRP condition or a treatment as usual (TAU) condition.  
TAU consisted of standard outpatient treatment provided within the agency, which used the 12-
step model along with process oriented care and psycho-educational groups.  The MBRP group 
met weekly for 2-hour group sessions, which were based on the MBRP treatment protocol and 
led by 2 master’s level therapists.  At the end of the 8-week intervention MBRP participants 
resumed treatment as usual.  Measurements were taken at baseline, post-intervention, and again 
at 2 and 4-month follow-up.  Attrition rates did not differ significantly between groups, and 
differences in treatment contact were controlled for by using treatment hours as a covariate in 
primary statistical analyses. 
Upon completion of the intervention, 85% of participants in the MBRP group reported 
continued use of meditation, and 54% reported continued practice 4-months post intervention.  
There were significant findings for the primary outcomes of the intervention.  Results indicated 
that participants in the MBRP group showed an average decrease of 86% in alcohol and drug use 
for each 2-month increase in linear time, as measured by The Timeline Followback (TLFB) 
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measure.  These were superior to the TAU results post-intervention and at 2-month follow up. 
MBRP participants also showed significant reduction in craving over time compared to the TAU 
group, as measured by The Penn Alcohol Craving Scale (PACS; Flannery, Volpicelli, Pettinati, 
1999).  Additionally, participants in the MBRP group had statistically significant increases in 
acceptance compared to the TAU group, as was reflected in changes in the Acceptance and 
Action Questionnaire (AAQ; Hayes et al., 2004).  While decreasing in the TAU group, facets of 
the Five Factor Mindfulness Questionnaire (FFMQ; Baer, Smith, Hopkins, Krietmeyer, & 
Toney; 2006) related to awareness-based-action increased in the MBRP group.   
At 2-month follow-up there appeared to be significant gains in primary treatment effects 
in the MBRP group compared to TAU, however these effects began to plateau at 4-month follow 
up. The authors proposed that this finding may be the result of a study design flaw, as the MBRP 
participants re-entered TAU at the conclusion of the 8-week MBRP intervention.  Techniques of 
thought suppression in the TAU group may have been counteractive to the skills introduced by 
MBRP.  This would likely change the active component of treatment, as reduction of thought 
suppression has been found to mediate the effects of mindfulness training on substance use 
(Bowen, Witkiewitz, Dillworth, & Marlatt, 2007).  In light of this finding, the authors proposed 
that a maintenance program or community resource supporting mindfulness practice may extend 
treatment benefits (Bowen et al., 2009).  This point requires clarification in future research.   
In addition to the surface benefits of the program upon craving and substance use, the 
content of MBRP also has tremendous potential for treating concurrent mood disorders.  As the 
program draws from components of MBCT, there are strong effects on detection of negative 
mood states.  A recent mediator moderator analysis indicated that depression was correlated with 
craving and substance use, and this relationship was eliminated after participation in the MBRP 
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group (Witkiewitz & Bowen, 2010). This study highlights the possibility of mindfulness training 
to influence the relationship between negative cognitive and emotional states and subjective 
experiences of craving. This may be particularly relevant in working with dually diagnosed 
clients with psychotic disorders, as the rate and intensity of positive symptoms are also highly 
correlated with mood states (Freeman & Garety, 2003; Smith et al., 2006). 
SUMMARY 
Unity in Treatment from the Bottom Up 
Clients with psychosis have historical been reduced to being a sum of their parts.  As a 
profession, psychology has evolved far beyond the initial mystery and fear that once framed the 
treatment of psychosis, and it is time to find a unity in treatment from the bottom up rather than 
the top down.  Researchers have come to recognize the neurological basis of psychosis, but also 
to understand these symptoms as a part of the larger spectrum of mental health.  As the field 
continues to evolve, it becomes the next natural step to address heightened rates of comorbid 
substance use in this population to inform treatment development.   
While substance use treatment and mental health interventions have often been described 
as juxtaposed, the newest wave of mindfulness-based approaches transcends this barrier.  
Because these treatment models take a step back from symptoms and instead treat the client’s 
relationship to symptoms, there is a common skill set that can be applied equally across 
comorbid conditions.  When broadening the lens of understanding dual diagnoses, overarching 
themes for treatment become clearer.  Both substance use and psychotic disorders have been 
characterized as chronic and relapsing conditions (Connors, Maisto, & Zywiak, 1996; Leshner, 
1999).  This factor may make them more amenable to the benefits of mindfulness-based 
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interventions, as chronic conditions were the initial focus that brought mindfulness to the West 
(Kabat-Zinn, 1990; Segal, Williams, & Teasdale, 2002).  Similar approaches are ideal for 
substance use and psychotic disorders, as relapse prevention for both has been largely based 
upon monitoring mood and environmental stressors that can trigger relapse.  Through 
mindfulness training, clients may come to better understand the transient nature of craving, 
mood, and positive symptoms.  Through heightened awareness of internal stimuli, sensations can 
be noticed as they arise with a sense of acceptance and compassion.  As both disorders carry 
heavy stigma in our culture, mindfulness adds the component of non-judgment, which may allow 
clients to de-center from a sense of judgment and over identification with symptoms. 
To this point dual diagnosis clients have been largely excluded from research, as studies 
looking into one disorder generally contain exclusion criteria for the other.  In constructing 
interventions for clients with psychotic disorders this is no longer acceptable, as nearly 50% of 
the population present with a co-occurring substance use disorder at some point in their lifetime.  
Considering the devastating effects of substance use disorders on symptom severity, healthcare 
costs, and long term outcomes (Dixon, 1999), it is essential that this population be represented in 
the research, and provided with holistic care.  The next logical phase in the evolution of 
treatment for psychotic disorders is the design of treatment interventions for dual diagnosis 
clients.  MBRP is an ideal candidate for modification with this population, and may be extended 
to provide specific skills for coping with the positive symptoms of psychosis.   
CONCLUSION 
The blending of cognitive behavioral therapy and mindfulness-based interventions could 
be a powerful next step in creating integrated care for individuals dually diagnosed with 
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psychotic disorders.  Future studies should focus on determining the impact of a modified MBRP 
intervention upon dimensions of substance use and craving, mindfulness and acceptance, and 
symptoms of psychosis and related distress in dually diagnosed populations.  CBT for 
schizophrenia and other psychotic disorders are becoming standard practice in many public 
healthcare settings, and it is possible within the framework of CBT to find manualized treatments 
that fit more tightly to the needs of dual diagnosis residents.  This progress could greatly improve 
the lives of those who are suffering from dual disorders, and positively impact the community 
and utilization of public healthcare dollars. 
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